These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25857341)

  • 1. Advances in Alzheimer's disease drug development.
    Rafii MS; Aisen PS
    BMC Med; 2015 Mar; 13():62. PubMed ID: 25857341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current therapies and new strategies for the management of Alzheimer's disease.
    Aderinwale OG; Ernst HW; Mousa SA
    Am J Alzheimers Dis Other Demen; 2010 Aug; 25(5):414-24. PubMed ID: 20601643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
    Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can We Treat Neuroinflammation in Alzheimer's Disease?
    Sánchez-Sarasúa S; Fernández-Pérez I; Espinosa-Fernández V; Sánchez-Pérez AM; Ledesma JC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drugs from Marine Organisms in Alzheimer's Disease.
    Russo P; Kisialiou A; Lamonaca P; Moroni R; Prinzi G; Fini M
    Mar Drugs; 2015 Dec; 14(1):5. PubMed ID: 26712769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core.
    Lin H; Li Q; Gu K; Zhu J; Jiang X; Chen Y; Sun H
    Curr Top Med Chem; 2017; 17(27):3000-3016. PubMed ID: 28714419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current strategies of pathogenetic therapy of Alzheimer's disease].
    Gavrilova SI; Zharikov GA
    Vestn Ross Akad Med Nauk; 2001; (7):13-8. PubMed ID: 11523421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug development for overcoming dementia in Japan].
    Nakamura H
    Rinsho Shinkeigaku; 2014; 54(12):1181-3. PubMed ID: 25672739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research.
    Jankowska A; Wesolowska A; Pawlowski M; Chlon-Rzepa G
    Curr Med Chem; 2018; 25(17):2045-2067. PubMed ID: 28554324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
    Gauthier S; Leuzy A; Rosa-Neto P
    Neurodegener Dis; 2014; 13(2-3):197-9. PubMed ID: 23942173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatments in Alzheimer's disease.
    Briggs R; Kennelly SP; O'Neill D
    Clin Med (Lond); 2016 Jun; 16(3):247-53. PubMed ID: 27251914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.
    Kosaraju J; Madhunapantula SV; Chinni S; Khatwal RB; Dubala A; Muthureddy Nataraj SK; Basavan D
    Behav Brain Res; 2014 Jul; 267():55-65. PubMed ID: 24667360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection.
    Caraci F; Spampinato S; Sortino MA; Bosco P; Battaglia G; Bruno V; Drago F; Nicoletti F; Copani A
    Cell Tissue Res; 2012 Jan; 347(1):291-301. PubMed ID: 21879289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.